MVASI 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
13/10/2022 
20/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02202 
bevacizumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/403/202202. 
R/0025 
Renewal of the marketing authorisation. 
21/07/2022 
21/09/2022 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of MVASI 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0027 
B.I.a.2.a - Changes in the manufacturing process of 
07/09/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/07/2022 
21/09/2022 
SmPC and PL 
Update of section 4.2 and 6.6 of the SmPC and section 3 of 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
the package leaflet by adding “Do not shake the vial”. The 
MAH also took this opportunity to make a small editorial  
correction to the contact details of the local representative 
in DE and aligned the annexes with the currently approved 
annexes of the reference product. 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
02102 
bevacizumab 
IB/0024 
B.I.a.1.f - Change in the manufacturer of AS or of a 
06/09/2021 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/07/2021 
08/07/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/2026 
This was an application for a variation following a 
08/07/2021 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
IB/0020 
B.I.b.2.a - Change in test procedure for AS or 
11/05/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
II/0017 
B.I.b.2.d - Change in test procedure for AS or 
04/03/2021 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/02/2021 
21/04/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IB/0018 
C.I.11.z - Introduction of, or change(s) to, the 
21/12/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
02002 
bevacizumab 
IB/0016/G 
This was an application for a group of variations. 
05/08/2020 
15/09/2020 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0015 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
21/07/2020 
15/09/2020 
SmPC and PL 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
IAIN/0014 
B.II.b.1.a - Replacement or addition of a 
22/06/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0012 
A.7 - Administrative change - Deletion of 
11/05/2020 
15/09/2020 
Annex II and 
manufacturing sites 
PL 
T/0011 
Transfer of Marketing Authorisation 
10/03/2020 
01/04/2020 
SmPC, 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0010/G 
This was an application for a group of variations. 
07/01/2020 
13/02/2020 
SmPC and PL 
Labelling and 
PL 
C.I.6.b - Change(s) to therapeutic indication(s) - 
Deletion of a therapeutic indication 
C.I.6.b - Change(s) to therapeutic indication(s) - 
Deletion of a therapeutic indication 
IAIN/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
30/10/2019 
13/02/2020 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
II/0008 
B.II.b.1.c - Replacement or addition of a 
12/09/2019 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
01902 
bevacizumab 
N/0006 
Minor change in labelling or package leaflet not 
24/04/2019 
13/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0005/G 
This was an application for a group of variations. 
29/11/2018 
06/02/2019 
Annex II 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
01802 
bevacizumab 
IG/0946 
B.II.b.2.c.1 - Change to importer, batch release 
04/06/2018 
06/02/2019 
PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0001 
B.II.b.2.c.1 - Change to importer, batch release 
12/02/2018 
06/02/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
